BBI-355

CHK1 inhibitor · Boundless Bio, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BBI-355, covering 2026-01-23 to 2026-01-23. Get the full timeline:

Most recent: Clinical Trial Update: Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications [Phase 1]

See pricing